The biphasic expression pattern of miR-200a and E-cadherin in epithelial ovarian cancer and its correlation with clinicopathological features

Current Pharmaceutical Design

Volumn 20, Issue 11, 2014, Pages 1888-1895

  Xu, Shaohua ^a   Xu, Peizhen ^a   Wu, Wei ^a,b   Ou, Yangjun ^a   Xu, Juan ^a   Zhang, Guanghua ^c   Li, Jinping ^d   Xu, Guofeng ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Nanjing Medical University   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

^d MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

E cadherin; Epithelial ovarian cancer; MicroRNA; miR 200a

Indexed keywords

MICRORNA 200A; UVOMORULIN; CADHERIN; MICRORNA; MIRN200 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BENIGN EPITHELIAL OVARIAN CYST; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DOWN REGULATION; EARLY DIAGNOSIS; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CARCINOMA; OVARY CYST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR DIFFERENTIATION; UPREGULATION; CANCER GRADING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; NEOPLASM; OVARY; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ADULT; AGED; CADHERINS; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARY; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84902520368     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990523     Document Type: Article

References (40)

1. Borley J, Wilhelm-Benartzi C, Brown R, Ghaem-Maghami S. Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review. Br J Cancer 2012; 107: 1069-74.
2. Berns EM, Bowtell DD. The changing view of high-grade serous ovarian cancer. Cancer Res 2012; 72: 2701-4.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
4. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572-7.
5. di Re F, Baiocchi G, Fontanelli R, et al. Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases. Gynecol Oncol 1996; 62: 360-5.
6. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351: 2519-29.
7. Boere IA, van der Burg ME. Review of dose-intense platinum and/or paclitaxel containing chemotherapy in advanced and recurrent epithelial ovarian cancer. Curr Pharm Des 2012; 18: 3741-53.
8. Zhang L, Volinia S, Bonome T, et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA 2008; 105: 7004-9.
9. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-69.
10. Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. microRNAs in cancer management. Lancet Oncol 2012; 13: e249-58.
11. Thornton JE, Gregory RI. How does Lin28 let-7 control development and disease? Trends Cell Biol 2012; 22: 474-82.
12. Lu Y, Govindan R, Wang L, et al. MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis 2012; 33: 1046-54.
13. Malumbres R, Sarosiek KA, Cubedo E, et al. Differentiation stagespecific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood 2009; 113: 3754-64.
14. Fabian MR, Sonenberg N. The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nat Struct Mol Biol 2012; 19: 586-93.
15. Karius T, Schnekenburger M, Dicato M, Diederich M. MicroRNAs in cancer management and their modulation by dietary agents. Biochem Pharmacol 2012; 83: 1591-601.
16. Nair VS, Maeda LS, Ioannidis JP. Clinical outcome prediction by microRNAs in human cancer: a systematic review. J Natl Cancer Inst 2012; 104: 528-40.
17. Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007; 67: 8699-707.
18. Nam EJ, Yoon H, Kim SW, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008; 14: 2690-5.
19. Dahiya N, Sherman-Baust CA, Wang TL, et al. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 2008; 3: e2436.
20. Hu X, Macdonald DM, Huettner PC, et al. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol 2009; 114: 457-64.
21. Horiuchi A, Konishi I. [Mechanism of ovarian cancer metastasis--changes in E-cadherin expression]. Nihon Rinsho 2004; 62 Suppl 10: 463-6.
22. Mateescu B, Batista L, Cardon M, et al. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med 2011; 17: 1627-35.
23. Bendoraite A, Knouf EC, Garg KS, et al. Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol 2010; 116: 117-25.
24. Cano A, Nieto MA. Non-coding RNAs take centre stage in epithelial-to-mesenchymal transition. Trends Cell Biol 2008; 18: 357-9.
25. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22: 894-907.
26. Shinozaki A, Sakatani T, Ushiku T, et al. Downregulation of microRNA-200 in EBV-associated gastric carcinoma. Cancer Res 2010; 70: 4719-27.
27. Hung CS, Liu HH, Liu JJ, et al. MicroRNA-200a and-200b Mediated Hepatocellular Carcinoma Cell Migration Through the Epithelial to Mesenchymal Transition Markers. Ann Surg Oncol 2012.
28. Braun J, Hoang-Vu C, Dralle H, Huttelmaier S. Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. Oncogene 2010; 29: 4237-44.
29. Xia H, Ng SS, Jiang S, et al. miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion. Biochem Biophys Res Commun 2010; 391: 535-41.
30. Katoh Y, Katoh M. Hedgehog signaling, epithelial-tomesenchymal transition and miRNA (review). Int J Mol Med 2008; 22: 271-5.
31. Burk U, Schubert J, Wellner U, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008; 9: 582-9.
32. Fuchs IB, Lichtenegger W, Buehler H, et al. The prognostic significance of epithelial-mesenchymal transition in breast cancer. Anticancer Res 2002; 22: 3415-9.
33. Tohma Y, Yamashima T, Yamashita J. Immunohistochemical localization of cell adhesion molecule epithelial cadherin in human arachnoid villi and meningiomas. Cancer Res 1992; 52: 1981-7.
34. Shapiro L, Fannon AM, Kwong PD, et al. Structural basis of cellcell adhesion by cadherins. Nature 1995; 374: 327-37.
35. van Roy F, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci 2008; 65: 3756-88.
36. Sawada K, Mitra AK, Radjabi AR, et al. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res 2008; 68: 2329-39.
37. Davidson B, Gotlieb WH, Ben-Baruch G, et al. E-Cadherin complex protein expression and survival in ovarian carcinoma. Gynecol Oncol 2000; 79: 362-71.
38. Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Lopes CS. Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas. Ann Oncol 2004; 15: 1535-42.
39. Aigner K, Dampier B, Descovich L, et al. The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 2007; 26: 6979-88.
40. Moes M, Le Bechec A, Crespo I, et al. A novel network integrating a miRNA-203/SNAI1 feedback loop which regulates epithelial to mesenchymal transition. PLoS One 2012; 7: e35440.